search
Back to results

A Trial of the ForeCYTE Breast Aspirator for Cytological Testing of Nipple Aspirate Fluid in Women 30-55 Years Old

Primary Purpose

Breast Cancer, Preneoplastic Conditions, BRCA

Status
Withdrawn
Phase
Phase 3
Locations
Israel
Study Type
Interventional
Intervention
ForeCYTE Breast Aspirator
Sponsored by
Atossa Therapeutics, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional screening trial for Breast Cancer, Preneoplastic Conditions, BRCA

Eligibility Criteria

30 Years - 55 Years (Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

  1. Healthy, female, age 30-55 years, from whom bi-lateral specimens can be obtained.

    The following additional considerations apply:

    • Women with prior mastectomy/lumpectomy may be considered for NAF-collection in the contralateral (non-operated) breast only if they were:

      • Stage I or Stage II at the time of surgery;
      • Have completed any and all hormonal therapy, chemotherapy, or targeted therapy at least one year prior to inclusion;
      • Are considered disease-free (NED- No Evidence of Disease) at the time of study entry;
    • Women under the age 30 may be enrolled if they are within 10 years of the age at diagnosis of breast cancer in a first-degree relative. No subject under the age of 21 may be enrolled.
  2. Any woman for whom NAF-cytology testing is considered to be beneficial by her physician. This includes, but is not limited to women with first- and/or second degree relatives with breast- or ovarian cancer. Known presence of a BRCA-1 or BRCA-2 germline mutation is allowed but not required. If known, any such mutation will be noted on the Case Report Form. The protocol does not provide for testing of women without known germ-line mutations.
  3. Non-lactating and non-pregnant.
  4. Good general health as determined by medical history, breast disease/cancer history, and clinical breast exam.
  5. Willing to give informed consent and follow study procedures as directed.

Exclusion Criteria

  1. Medical condition/psychiatric conditions making subjects a poor candidate for study, as determined by the Principal Investigator.
  2. Pregnancy or suspicion of pregnancy.
  3. Open cutaneous wounds or atopic dermatitis in the area of the nipple-areolar complex.
  4. No or inverted nipple on the breast unfit for fluid collection, or significant prior surgery in the area of the nipple-areolar complex.
  5. Participation in an investigational drug or device study less than 30 days prior to enrollment in this study.
  6. Pregnancy, childbirth, or lactation less than 90 days prior to enrollment in this study.
  7. Acute illness, including taking antibiotics, analgesics, antipyretics and/or cold medications less than 7 days prior to enrollment in this study.

Sites / Locations

  • The BARUCH PADEH Medical Center
  • Ziv Medical Center

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

ForeCYTE Breast Aspirator - Nipple Aspirate Fluid Collection

Arm Description

Nipple Aspirate is collected using the ForeCYTE Breast Aspirator

Outcomes

Primary Outcome Measures

NAF cytological classification(s), according to the modified King Classification.

Secondary Outcome Measures

The IBIS (Tyrer-Cuzick) risk score (10-year and lifetime breast cancer risk estimate.
Safety, as reported by adverse events experienced after NAF collection with ForeCYTE Breast Aspirator
micro-RNA (subgroup analysis of BRCA mutation carriers only)
development of micro-RNA panel that signals the transition to breast cancer

Full Information

First Posted
September 1, 2015
Last Updated
January 21, 2016
Sponsor
Atossa Therapeutics, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT02539615
Brief Title
A Trial of the ForeCYTE Breast Aspirator for Cytological Testing of Nipple Aspirate Fluid in Women 30-55 Years Old
Official Title
A Single-arm, Multi-center Trial of the ForeCYTE Breast Aspirator for Sample Collection and Cytological Testing of Nipple Aspirate Fluid in Women 30-55 Years of Age
Study Type
Interventional

2. Study Status

Record Verification Date
January 2016
Overall Recruitment Status
Withdrawn
Study Start Date
September 2015 (undefined)
Primary Completion Date
December 2015 (Anticipated)
Study Completion Date
March 2016 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Atossa Therapeutics, Inc.

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to measure the performance of the ForeCYTE Breast Aspirator for the collection and processing of Nipple Aspirate Fluid (NAF) specimens for cytology. Including collecting, processing and shipping samples, training staff, processing samples, sample interpretation and accurate and timely reporting in a manner resembling routine clinical use. The study will include a subset of patients who are known carriers of a BRCA germline mutation. NAF from this subset will be submitted for molecular testing in addition to cytology.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Breast Cancer, Preneoplastic Conditions, BRCA

7. Study Design

Primary Purpose
Screening
Study Phase
Phase 3
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
0 (Actual)

8. Arms, Groups, and Interventions

Arm Title
ForeCYTE Breast Aspirator - Nipple Aspirate Fluid Collection
Arm Type
Experimental
Arm Description
Nipple Aspirate is collected using the ForeCYTE Breast Aspirator
Intervention Type
Device
Intervention Name(s)
ForeCYTE Breast Aspirator
Primary Outcome Measure Information:
Title
NAF cytological classification(s), according to the modified King Classification.
Time Frame
1 day (single time point)
Secondary Outcome Measure Information:
Title
The IBIS (Tyrer-Cuzick) risk score (10-year and lifetime breast cancer risk estimate.
Time Frame
1 day (single time point)
Title
Safety, as reported by adverse events experienced after NAF collection with ForeCYTE Breast Aspirator
Time Frame
1 day (single time point)
Title
micro-RNA (subgroup analysis of BRCA mutation carriers only)
Description
development of micro-RNA panel that signals the transition to breast cancer
Time Frame
1 day (single time point)

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Healthy, female, age 30-55 years, from whom bi-lateral specimens can be obtained. The following additional considerations apply: Women with prior mastectomy/lumpectomy may be considered for NAF-collection in the contralateral (non-operated) breast only if they were: Stage I or Stage II at the time of surgery; Have completed any and all hormonal therapy, chemotherapy, or targeted therapy at least one year prior to inclusion; Are considered disease-free (NED- No Evidence of Disease) at the time of study entry; Women under the age 30 may be enrolled if they are within 10 years of the age at diagnosis of breast cancer in a first-degree relative. No subject under the age of 21 may be enrolled. Any woman for whom NAF-cytology testing is considered to be beneficial by her physician. This includes, but is not limited to women with first- and/or second degree relatives with breast- or ovarian cancer. Known presence of a BRCA-1 or BRCA-2 germline mutation is allowed but not required. If known, any such mutation will be noted on the Case Report Form. The protocol does not provide for testing of women without known germ-line mutations. Non-lactating and non-pregnant. Good general health as determined by medical history, breast disease/cancer history, and clinical breast exam. Willing to give informed consent and follow study procedures as directed. Exclusion Criteria Medical condition/psychiatric conditions making subjects a poor candidate for study, as determined by the Principal Investigator. Pregnancy or suspicion of pregnancy. Open cutaneous wounds or atopic dermatitis in the area of the nipple-areolar complex. No or inverted nipple on the breast unfit for fluid collection, or significant prior surgery in the area of the nipple-areolar complex. Participation in an investigational drug or device study less than 30 days prior to enrollment in this study. Pregnancy, childbirth, or lactation less than 90 days prior to enrollment in this study. Acute illness, including taking antibiotics, analgesics, antipyretics and/or cold medications less than 7 days prior to enrollment in this study.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jelle Kylstra
Organizational Affiliation
Atossa Therapeutics, Inc.
Official's Role
Study Director
Facility Information:
Facility Name
The BARUCH PADEH Medical Center
City
Poriya
State/Province
Lower Galilee
ZIP/Postal Code
15208
Country
Israel
Facility Name
Ziv Medical Center
City
Zefat
State/Province
Upper Galilee
ZIP/Postal Code
13100
Country
Israel

12. IPD Sharing Statement

Learn more about this trial

A Trial of the ForeCYTE Breast Aspirator for Cytological Testing of Nipple Aspirate Fluid in Women 30-55 Years Old

We'll reach out to this number within 24 hrs